. 2019 Nov 21;8(12):1607–1617. doi: 10.1530/EC-19-0408
This work is licensed under a Table 1.
Baseline characteristics of the study population.
| n | Total | Women | Men | |
|---|---|---|---|---|
| n | 1326 | 623 | 703 | |
| Age (years) | 1326 | 66 (7) | 66 (7) | 66 (7) |
| Current smokers (%) | 1326 | 15.8 (13.9; 17.9) | 13.3 (10.8; 16.2) | 18.1 (15.3; 21.1) |
| Glucose tolerance status (%) | 1326 | |||
| NGT | – | 53.0 (50.3; 55.7) | 58.9 (54.9; 62.8) | 47.8 (44.0; 51.6) |
| Pre-diabetes | – | 35.6 (33.0; 38.2) | 33.1 (29.4; 36.9) | 37.8 (34.2; 41.5) |
| Screen detected diabetes | – | 11.4 (9.7; 13.2) | 8.0 (6.0; 10.4) | 14.4 (11.9; 17.2) |
| BMI (kg/m2) | 1326 | 27.1 (4.5) | 26.6 (5.1) | 27.5 (3.9) |
| Systolic blood pressure (mmHg) | 1324 | 133 (17) | 130 (18) | 136 (16) |
| Diastolic blood pressure (mmHg) | 1324 | 81 (10) | 81 (10) | 82 (10) |
| Fasting plasma glucose (mmol/L) | 1326 | 6.0 (0.8) | 5.9 (0.7) | 6.1 (0.8) |
| 2-h plasma glucose (mmol/L) | 1325 | 6.8 (2.3) | 6.6 (2.1) | 7.0 (2.4) |
| Fasting serum insulin (pmol/L) | 1325 | 37 (25; 55) | 36 (24; 50) | 39 (26; 60) |
| 2-h serum insulin (pmol/L) | 1324 | 184 (110; 313) | 185 (117; 299) | 181 (101; 325) |
| ISI0-120 | 1321 | 36.9 (25.9; 48.8) | 37.2 (27.6; 48.8) | 36.4 (24.0; 49.2) |
| Insulinogenic index | 1314 | 8.3 (5.2; 13.7) | 9.0 (5.3; 14.4) | 7.9 (5.2; 13.1) |
| Physical activity measures | ||||
| PAEE (kJ/kg/day) | 1267 | 32.7 (15.6) | 31.0 (14.8) | 34.3 (16.1) |
| VPA (h/day) | 1104 | 0.00 (0.00; 0.01) | 0.00 (0.00; 0.00) | 0.00 (0.00; 0.02) |
| MVPA (h/day) | 1104 | 0.47 (0.19; 0.90) | 0.37 (0.16; 0.76) | 0.54 (0.22; 1.02) |
| MVPA ≥0.5 h/day (%) | 1104 | 33.5 (29.8; 37.4) | 38.9 (36.3; 41.6) | 43.7 (40.0; 47.4) |
| LPA (h/day) | 1104 | 4.63 (3.39; 5.90) | 4.61 (3.30; 5.92) | 4.67 (3.41; 5.85) |
| Sedentary (h/day) | 1104 | 12.2 (2.4) | 12.3 (2.4) | 12.1 (2.3) |
| CRF (ml O2/kg/min) | 793 | 29.9 (5.4) | 28.7 (5.1) | 30.8 (5.4) |
| Biochemical measures | ||||
| Plasma GLP-1, tAUC0-30 (pmol/L × min) | 1310 | 615 (450; 825) | 645 (465; 870) | 585 (435; 780) |
| Plasma GLP-1, tAUC0-120 (pmol/L × min) | 1303 | 2805 (2040; 3795) | 3075 (2280; 4200) | 2595 (1935; 3480) |
| Plasma GLP-1, rAUC0–30 (fold increase) | 1310 | 1.7 (1.3; 2.5) | 1.9 (1.5; 2.9) | 1.6 (1.3; 2.1) |
| Plasma GLP-1, rAUC0–120 (fold increase) | 1303 | 2.0 (1.5; 3.1) | 2.3 (1.7; 3.7) | 1.8 (1.4; 2.6) |
Data are the means (s.d.), medians (interquartile range) or percentages (95% CI).
CRF, cardiorespiratory fitness; GLP-1, glucagon-like peptide-1; ISI0-120, insulin sensitivity index; LPA, light physical activity; MVPA, moderate-to-vigorous physical activity; NGT, normal glucose tolerance; PAEE, physical activity energy expenditure; VPA, vigorous physical activity.